These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10459813)

  • 21. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice.
    Saxena S; Ghosh PC
    Pharm Res; 2000 Oct; 17(10):1236-42. PubMed ID: 11145229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.
    Usman F; Nopparat J; Javed I; Srichana T
    Drug Deliv Transl Res; 2020 Feb; 10(1):59-69. PubMed ID: 31368043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans.
    Takemoto K; Yamamoto Y; Ueda Y
    Microbiol Immunol; 2006; 50(8):579-86. PubMed ID: 16924142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits.
    Chavanet P; Duong M; Buisson M; Hamel H; Dubois C; Bonnin A; Portier H
    J Antimicrob Chemother; 1997 Mar; 39(3):427-30. PubMed ID: 9096196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity.
    Sabra R; Zeinoun N; Sharaf LH; Ghali R; Beshara G; Serhal H
    Pharmacol Toxicol; 2001 Apr; 88(4):168-75. PubMed ID: 11322173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High purity amphotericin B.
    Cleary JD; Chapman SW; Swiatlo E; Kramer R
    J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.
    López-Sánchez A; Pérez-Cantero A; Torrado-Salmerón C; Martin-Vicente A; García-Herrero V; González-Nicolás MÁ; Lázaro A; Tejedor A; Torrado-Santiago S; García-Rodríguez JJ; Capilla J; Torrado S
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.
    Cacciapuoti A; Gurnani M; Halpern J; Norris C; Patel R; Loebenberg D
    Antimicrob Agents Chemother; 2005 Feb; 49(2):638-42. PubMed ID: 15673745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis.
    Delmas G; Park S; Chen ZW; Tan F; Kashiwazaki R; Zarif L; Perlin DS
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2704-7. PubMed ID: 12121962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.
    Clemons KV; Stevens DA
    J Antimicrob Chemother; 1992 Sep; 30(3):353-63. PubMed ID: 1452501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antifungal activity against Candida albicans of starch Pickering emulsion with thymol or amphotericin B in suspension and calcium alginate films.
    Cossu A; Wang MS; Chaudhari A; Nitin N
    Int J Pharm; 2015 Sep; 493(1-2):233-42. PubMed ID: 26231107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.
    Echevarría I; Barturen C; Renedo MJ; Trocóniz IF; Dios-Viéitez MC
    Antimicrob Agents Chemother; 2000 Apr; 44(4):898-904. PubMed ID: 10722488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.
    El-Azizi M; Farag N; Khardori N
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():21. PubMed ID: 25885806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Sievers TM; Kubak BM; Wong-Beringer A
    J Antimicrob Chemother; 1996 Sep; 38(3):333-47. PubMed ID: 8889711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.
    Risovic V; Boyd M; Choo E; Wasan KM
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3339-42. PubMed ID: 14506053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model.
    Shuford JA; Rouse MS; Piper KE; Steckelberg JM; Patel R
    J Infect Dis; 2006 Sep; 194(5):710-3. PubMed ID: 16897672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amphotericin B and amphotericin B methyl ester ascorbate. I. Chemotherapeutic activity against Candida albicans, Cryptococcus neoformans, and Blastomyces dermatitidis in mice.
    Gadebusch HH; Pansy F; Klepner C; Schwind R
    J Infect Dis; 1976 Nov; 134(5):423-7. PubMed ID: 792355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans.
    Brime B; Molero G; Frutos P; Frutos G
    Eur J Pharm Sci; 2004 Aug; 22(5):451-8. PubMed ID: 15265515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation.
    Alvarez C; Andes DR; Kang JY; Krug C; Kwon GS
    Pharm Res; 2017 May; 34(5):1115-1124. PubMed ID: 28205003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.